Heart Procedure Outperforms Medication for Atrial Fibrillation, Study Finds
A minimally invasive heart procedure developed by Boston Scientific has been shown to significantly outperform standard drug therapy in treating persistent atrial fibrillation (AFib), according to new clinical trial data.
AFib, a common heart rhythm disorder, increases the risk of stroke fivefold and is associated with higher chances of heart failure and premature death. While current treatment guidelines typically recommend medication as the first line of therapy—especially for persistent cases—new findings suggest earlier procedural intervention may offer superior outcomes.
The study, presented at Heart Rhythm 2026 and published in The New England Journal of Medicine, involved 310 patients with previously untreated persistent AFib. Participants were randomly assigned to receive either antiarrhythmic drug therapy or undergo pulsed-field catheter ablation using Boston Scientific’s Farapulse system.
The ablation procedure involves guiding thin catheters through blood vessels into the heart, where controlled bursts of electrical energy are delivered to eliminate tissue responsible for abnormal electrical signals—effectively “resetting” the heart’s rhythm.
After one year, 56% of patients who underwent the ablation procedure remained free of abnormal heart rhythms, compared with just 30% of those treated with medication alone. Importantly, the rate of serious adverse events was similar between both groups.
Lead investigator Jason Andrade noted that the findings challenge the traditional stepwise treatment approach. “These results indicate that earlier intervention with ablation—even in more advanced cases—can lead to better disease control and improved patient outcomes,” he said.
Blood-Filtering Technique Shows Promise in Managing Preeclampsia
In a separate development, researchers have reported encouraging early results for a novel blood-filtering treatment aimed at managing preeclampsia, a potentially life-threatening pregnancy complication characterized by high blood pressure.
Currently, the only definitive treatment for preeclampsia is early delivery of the baby, which can increase the risk of complications associated with premature birth. The new approach could offer a way to prolong pregnancy safely.
The experimental treatment targets a placental protein known as sFlt-1, which plays a key role in the progression of preeclampsia. Elevated levels of this protein are associated with worsening maternal blood pressure.
Using a technique called apheresis, researchers removed excess sFlt-1 from the bloodstream. The approach was first tested in animal models and later in a small pilot study involving 16 women with early-onset preeclampsia.
Findings published in Nature Medicine suggest that the procedure may help slow disease progression and reduce the need for early delivery. However, researchers emphasized that larger clinical trials are necessary to confirm safety and effectiveness before the treatment can be widely adopted.
